Tobramycin Injectable (Iv, Im) Suppliers & Bulk Manufacturers
Available Forms: Injectable (IV, IM)
Available Strengths: 10 mg/mL, 40 mg/mL, 80 mg/mL
Reference Brands: Bethkis, Tobi (US)
Category:
Antibiotics
Tobramycin inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing faulty protein production and bacterial death. It is effective against serious gram-negative infections, including Pseudomonas. Benefits include rapid bacterial eradication, broad-spectrum activity, and suitability for severe infections in hospital settings, when used under proper supervision.
Tobramycin Injectable (IV, IM) is available in Injectable (IV, IM)
and strengths such as 10 mg/mL, 40 mg/mL, 80 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tobramycin Injectable (IV, IM) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tobramycin Injectable (IV, IM) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tobramycin injectable is approved in the EU and US for severe gram-negative bacterial infections, including Pseudomonas aeruginosa. In the EU, brands like Tobramycin are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic formulations are available. Both regions require detailed dossiers, including clinical trial results, quality control, and pharmacovigilance plans for approval and ongoing safety monitoring. Due to its potent activity and toxicity risks, strict prescribing, administration protocols, and monitoring are enforced. For expert regulatory support and dossier management, visit PharmaTradz. We ensure seamless market access, adhering to European and US standards for safe, effective antimicrobial therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing